US FDA Approves GSK's AREXVY, the World's First Respiratory Syncytial Virus (RSV) Vaccine for Older Adults

Author's Avatar
May 03, 2023

GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved AREXVY(respiratory syncytial virus vaccine, adjuvanted) for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older. Thisis the first RSV vaccine for older adults to be approved anywhere in the world.